finance.yahoo.com
Cure8 news brief
Why This Matters
New long-term and real-world data about risankizumab and upadacitinib may influence treatment choices and expectations about symptom relief, steroid-sparing effects, treatment persistence, and hospitalization risk for people with Crohn's disease or ulcerative colitis.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis, people on or considering biologic/JAK therapies, clinicians managing IBD, and researchers tracking real-world and long-term treatment outcomes.
Study Snapshot
Story typeCompany update
Evidence typePatient Education
Source depthFull source text
What To Know
AbbVie's press release summarizes 18 abstracts it presented at DDW 2026, focusing on long-term and real-world data for risankizumab (SKYRIZI) and upadacitinib (RINVOQ) in Crohn's disease and ulcerative colitis.
The release highlights sustained symptom and endoscopic improvements, reduced steroid use, lower real-world switching rates for risankizumab versus other biologics, and lower hospitalization/ED odds after switching to upadacitinib versus dose escalation.
It also references phase 3 data in perianal fistulizing Crohn's disease showing endoscopic improvements with upadacitinib. This is a company press release summarizing multiple abstracts and real-world analyses rather than a peer-reviewed study report.
It is useful for awareness of new data presented at DDW but does not replace reading the individual abstracts or independent studies for details. If you want details that affect care decisions (like exact outcomes, populations, or safety data), look up the individual DDW abstracts or peer-reviewed publications noted in the release.
Keep In Mind
This is a company-issued press release summarizing multiple DDW abstracts and real-world analyses. Abstracts and full study details should be consulted for methods, exact results, and safety data. Press releases can emphasize favorable findings; independent review is recommended before changing treatment.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfinance.yahoo.com
Indexed viaBing News
Source typeCompany update
PublishedMay 5, 2026, 5:32 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
AbbVie (ABBV): 10 Best Low Risk Stocks to Buy in 2026
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
AbbVie Data Underscores Immunology Growth Potential With SKYRIZI And RINVOQ
New long-term and real-world data on SKYRIZI and RINVOQ were presented at DDW, which may influence how clinicians, payers, and patients view these options for Crohn's disease and ulcerative colitis.
Lilly secures FDA approval for Omvoh to treat Crohn's disease
A new FDA-approved biologic option (Omvoh/mirikizumab) is now available for adults with moderately to severely active Crohn’s disease, potentially expanding treatment choices.